Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

None of the cell and gene therapies that reached the final regulatory submission stage were rejected by the FDA.

Renier Brentjens, a CAR T-cell pioneer, views armored CAR T-cells as a promising avenue for treating solid tumors and ...

Knocking out a single gene reprograms part of the large intestine to function like the nutrient-absorbing small intestine. In ...

Head and neck cancers often begin in the mouth, throat, or voice box. They're among the most common cancers in the world, ...

Out of the shadows, new CDMO Artis BioSolutions has decloaked on a mission to tackle the tricky production process for ...

Learn about the global cell therapy industry in 2022, including players in the space; key licensing deals, and the effect of ...

The $150 million will also go toward Atsena’s preclinical pipeline and expand the use of the biotech’s spreading AAV.SPR ...

Sebastien Beauzile, 21, is the first New Yorker to have received the breakthrough Lyfgenia treatment, according to the New ...

If preclinical findings were translated into the clinic, they could shorten the CAR-T generation lead time from two weeks to ...

Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...